Think of this as a definitive conversation about injection sites and techniques, built from years of experience in the biotechnology space
Call (954) 551-3508 or book online now
Semaglutide or Tirzepatide: GLP-1 receptor agonists work through entirely different mechanisms (appetite suppression, glucose regulation, delayed gastric emptying) compared to AOD-9604s direct lipolytic effects

Semaglutide Clinical Data The STEP trial program represents the most comprehensive clinical evaluation of any GLP-1 receptor agonist for weight management: STEP 1: 14.9% mean body weight loss over 68 weeks (Wilding et al., NEJM , 2021) STEP 3: 16.0% with intensive behavioral therapy over 68 weeks STEP 5: Sustained 15.2% weight loss maintained at 104 weeks with continued treatment SELECT trial: Demonstrated 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in addition to weight loss, establishing cardiovascular benefit (Lincoff et al., NEJM , 2023) The SELECT trial result is particularly significant because it demonstrated that semaglutide provides cardiovascular protection independent of weight loss, a benefit that has not been established for tesofensine
We are blessed to have Nurse Fumnilo